T2-imaging of area-at-risk predicts recovery of cardiac function in a canine model of acute myocardial infarction
© Bourque et al; licensee BioMed Central Ltd. 2009
Published: 28 January 2009
Infarct size is the strongest predictor of subsequent outcomes and remains an important therapeutic target. Myocardial edema measured by T2-weighted magnetic resonance (MR) imaging identifies the ischemic area-at-risk and predicts infarct size, allows more accurate evaluation of novel anti-ischemic therapies, and may be associated with stunning and long-term recovery of function.
We sought to identify the extent of infarcted and at-risk myocardium and correlate these markers with post-infarct recovery of myocardial function.
Five dogs (mean weight 18.9 kgs) underwent successful 2-hour complete occlusion of the left-circumflex artery and collaterals after baseline functional cine imaging. They subsequently underwent 48-hour and 4-week complete left-ventricular (LV) short-axis MR imaging on a 1.5 Tesla scanner using SSFP-cine (TE 1.4 ms, TR 35.3 ms, voxel size 0.6 × 1 × 7 mm3), ACUTE T2-weighted (TE 1.9 ms, TR 168.1 ms, voxel size 0.6 × 0.9 × 7 mm3), and phase-sensitive, inversion recovery late Gadolinium (0.15 mmol/kg Magnevist) enhancement sequences (LGE, TE 3.4 ms, TR 548 ms, voxel size 0.5 × 0.8 × 7 mm3). The percentages of LGE and T2 hyperenhacement were identified through intensity threshold testing, 5 standard devitations (SDs) and 2 SDs above the reference myocardium respectively. All outcome variables were given as mean percentages ± SDs.
The area-at-risk estimated by T2-weighted MR imaging correlates with recovery of myocardial infarction in an acute-MI canine model. Further evaluation of this method will maximize our ability to prognosticate and guide therapy post-infarction. Increasing the proportion of myocardial salvage from the initial area-at-risk should serve as an important therapeutic target. This imaging technique may become a significant marker of treatment efficacy and prognosis.
This article is published under license to BioMed Central Ltd.